Life Sciences


ValiRx aims to deliver high returns by applying its scientific, management and entrepreneurial expertise to projects in which it has equity and rights. These projects have intelligent acquisition and manageable development costs, but have the potential to significantly increase in value prior to their crystalisation.

They are building a portfolio of innovative products through strategic investment into areas relating to the treatment and diagnosis of cancer. They work regularity with companies offering technologies complementary to our own.

Market: AIM

Ticker: VAL

Lead analyst: Dr Martin Hall